66304-1-Ig

antibody from Proteintech Group

Targeting: CD47 IAP, MER6, OA3

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Flow cytometry (Data presented on provider website)

Antibody Data

Product number

66304-1-Ig

Provider

Proteintech Group

Product name

CD47 antibody

Antibody type

Monoclonal

Description

KD/KO validated CD47 antibody (Cat. #66304-1-Ig) is a mouse monoclonal antibody that shows reactivity with human and has been validated for the following applications: FC, WB,ELISA.

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Isotype

IgG

Antibody clone number

1E1D8

Vial size

20ul, 150ul

References

Submitted references

Bispecific Nanobody-Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors.

Wang Y, Chen J, Zhang S, Jiang H, Zhu J, Jiang G, Liu Y, Zhu Y, Li J
Small (Weinheim an der Bergstrasse, Germany) 2024 Jun;20(25):e2308265

---

Endothelial transferrin receptor 1 contributes to thrombogenesis through cascade ferroptosis.

Ma H, Huang Y, Tian W, Liu J, Yan X, Ma L, Lai J
Redox biology 2024 Apr;70:103041

---

Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1.

Zeng Z, Lin C, Zhang MC, Kossinna P, Wang P, Cao D, Wang J, Xu M, Wang X, Li Q, Xu X, Yang H, Zhu S, Liu GR, Xie K, Yang J, Luo Y, Wang Y, Zhang XH, Lin J, Chen H, Liu SL, Liu H
Phytotherapy research : PTR 2023 Oct;37(10):4722-4739

---

Platelet-mimetic nano-sensor for combating postoperative recurrence and wound infection of triple-negative breast cancer.

Liu Y, Qi Y, Chen C, Jin Y, Du S, Qiao J, Yao J
Journal of controlled release : official journal of the Controlled Release Society 2023 Oct;362:396-408

---

Long Circulating Cancer Cell-Targeted Bionic Nanocarriers Enable Synergistic Combinatorial Therapy in Colon Cancer.

Zheng Y, Guo W, Hu L, Xiao Z, Yang X, Cao Z, Cao J
ACS applied materials & interfaces 2023 May 17;15(19):22843-22853

---

Remodeling Collagen Microenvironment in Liver Using a Biomimetic Nano-Regulator for Reversal of Liver Fibrosis.

Liang Y, Wang J, Xu C, Han W, Wu S, Wu Y, Zhang J, Liu J, Zhang Z, Shi J, Zhang K
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023 Jun;10(18):e2300127

---

B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy.

Chen S, Zhan S, Ding S, Zhang Q, Xuan H, Zhang X, Cao L
Journal of cancer research and clinical oncology 2023 Dec;149(18):16609-16621

---

CD47 interactions with exportin-1 limit the targeting of m(7)G-modified RNAs to extracellular vesicles.

Kaur S, Saldana AC, Elkahloun AG, Petersen JD, Arakelyan A, Singh SP, Jenkins LM, Kuo B, Reginauld B, Jordan DG, Tran AD, Wu W, Zimmerberg J, Margolis L, Roberts DD
Journal of cell communication and signaling 2022 Sep;16(3):397-419

---

Erythrocyte-biomimetic nanosystems to improve antitumor effects of paclitaxel on epithelial cancers.

Song M, Dong S, An X, Zhang W, Shen N, Li Y, Guo C, Liu C, Li X, Chen S
Journal of controlled release : official journal of the Controlled Release Society 2022 May;345:744-754

---

Naturally Equipped Urinary Exosomes Coated Poly (2-ethyl-2-oxazoline)-Poly (D, L-lactide) Nanocarriers for the Pre-Clinical Translation of Breast Cancer.

Ni J, Mi Y, Wang B, Zhu Y, Ding Y, Ding Y, Li X
Bioengineering (Basel, Switzerland) 2022 Aug 3;9(8)

---

Bone-targeted erythrocyte-cancer hybrid membrane-camouflaged nanoparticles for enhancing photothermal and hypoxia-activated chemotherapy of bone invasion by OSCC.

Chen H, Deng J, Yao X, He Y, Li H, Jian Z, Tang Y, Zhang X, Zhang J, Dai H
Journal of nanobiotechnology 2021 Oct 26;19(1):342

---

MicroRNA-148a-3p inhibits cancer progression and is a novel screening biomarker for gastric cancer.

Bao C, Guo L
Journal of clinical laboratory analysis 2020 Oct;34(10):e23454

---

Seedless preparation of Au nanorods by hydroquinone assistant and red blood cell membrane camouflage.

Li J, Wang W, Zhang X, Yao H, Wei Z, Li X, Mu X, Jiang J, Zhang H
RSC advances 2018 Jun 8;8(38):21316-21325